|The Beta1 Integrin n/a (Catalog #MBS584405) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Beta1 Integrin, Human, mAb BV7, FITC reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s Beta1 Integrin can be used in a range of immunoassay formats including, but not limited to, Flow Cytometry (FC/FACS), Immunoassay (IA), Western Blot (WB).
Application Notes: FC: Antibody BV7 stains the extracellular domain of beta-1 integrin. HUVEC cells were fixed in 4% paraformaldehyde before staining. Mouse IgG1 isotype was used as negative.
Application Use: For flow cytometry and Western blotting dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. Researchers should empirically determine the suitability of the Beta1 Integrin n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Product Description: Monoclonal antibody BV7 binds to human beta1 integrin chain present on tumor cells. BV7 is active on HT-29 colon carcinoma cells and on HCCP-2998 tumor cells. BV7 binds to several other tumor cells (MG3 osteosarcoma, A375 melanoma, MHCC-1410 and Lovo colon carcinoma) but does not affect adhesion to endothelial cells.
Conjugate: FITC. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Beta1 Integrin are readily searchable from our website. Different antibodies against the same target such as Beta1 Integrin may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.